Other languages Camurus AB

Equities

CAMX

SE0007692850

Real-time Estimate Cboe Europe Other stock markets 10:13:52 2024-04-29 am EDT			5-day change	1st Jan Change
492.6 ^SEK	+0.53%		+3.49%	-8.62%

Apr. 17	Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
Apr. 02	Camurus AB Announces Board Resignations	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Camurus AB Announces Board Resignations	Apr. 02
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	Mar. 05
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	Mar. 05
OPINIONES DE LOS ANALISTAS DEL DÍA : Acciona, Amadeus, Acs, Endesa, Ferrari, Heineken, Iberdrola, Prosegur, Salvatore Ferragamo...	Mar. 04
AVIS D'ANALYSTES DU JOUR : Sanofi, Stellantis, Orange, STMicroelectronics, OVH, UCB, Valeo...	Mar. 04
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
Camurus AB Provides Earnings Guidance for the Full Year 2024	Feb. 15
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	Feb. 13
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	Feb. 08
Camurus Submits US FDA New Drug Application for Hormonal Disorder Treatment	Dec. 21
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	Dec. 21
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	Dec. 20
Camurus Concludes Enrollment in Phase 3 Study of Neuroendocrine Tumors Vaccine	Dec. 14
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	Dec. 14
Camurus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Camurus AB Raises Earnings Guidance for the Year 2023	23-10-23
Camurus Appoints Nomination Committee for the Annual General Meeting 2024	23-10-18
AVIS D'ANALYSTES DU JOUR : Alstom, Accor, Thales, Euroapi, LVMH, Ubisoft, Worldline, Pandora...	23-10-10
Camurus Launches Opioid Use Disorder Injection in US	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Camurus AB

Equities

CAMX

SE0007692850

Other languages

Filters